Lab Med Online.  2023 Oct;13(4):341-348. 10.47429/lmo.2023.13.4.341.

Performance Evaluation of Access HIV Combo V2 Assay

• Lee H
• Choi YJ
• Song EY

• KMID: 2552761
• DOI: http://doi.org/10.47429/lmo.2023.13.4.341

Abstract

Background
The recently introduced 4th generation HIV assay, Access HIV Combo V2 (Bio-Rad Laboratories, USA), can detect the HIV-2 p26 antigen, which has not been targeted by other 4th generation HIV assays. We evaluated the clinical utility of the Access HIV Combo V2 assay.
Methods
A total of 1,100 negative samples evaluated using the ARCHITECT HIV Ag/Ab Combo assay (Abbott Laboratories, USA) in Seoul National University Hospital (SNUH) during September 2021 and October 2021 were included. Additional 100 positive samples, including 25 sera from SNUH that showed positive ARCHITECT HIV Ag/Ab Combo and western blot/RNA assay results, along with 60 sera from Chung-Ang University Hospital Biobank and 15 commercial samples (9 HIV-1 p24 antigen-, 3 HIV-2 antibody-, 3 HIV-2 p26 antigen-positive), were included. Three seroconversion panel samples were tested for seroconversion sensitivity. Three levels (NC, PC1, and PC2) of QC materials were tested for precision 5 times a day for 5 consecutive days, and carry-over was also evaluated.
Results
Sensitivity and specificity of Access HIV Combo V2 were 100.00% (95% CI: 96.38–100.0%) and 99.82% (95% CI: 99.34–99.98%), respectively. Access HIV Combo V2 showed seroconversion sensitivity comparable to that of ARCHITECT HIV Ag/Ab Combo and Elecsys HIV combi PT (Roche Diagnostics, Germany). Within-laboratory CV were 9.5%, 3.7%, and 3.9% for NC, PC1, and PC2, respectively, and no carry-over was observed.
Conclusions
Access HIV Combo V2 assay showed excellent sensitivity and specificity, good precision, and no carry-over. Its seroconversion sensitivity was comparable to that of existing 4th generation HIV assays.

Keyword

HIV-1; HIV-2; Sensitivity; Specificity; Seroconversion

Reference

1. Hurt CB, Nelson JAE, Hightow-Weidman LB, Miller WC. 2017; Selecting an HIV test: a narrative review for clinicians and researchers. Sex Transm Dis. 44:739–46. DOI: 10.1097/OLQ.0000000000000719. PMID: 29140890. PMCID: PMC5718364.

2. Alexander TS. 2016; Human immunodeficiency virus diagnostic testing: 30 years of evolution. Clin Vaccine Immunol. 23:249–53. DOI: 10.1128/CVI.00053-16. PMID: 26936099. PMCID: PMC4820517.

3. Gürtler L, Mühlbacher A, Michl U, Hofmann H, Paggi GG, Bossi V, et al. 1998; Reduction of the diagnostic window with a new combined p24 antigen and human immunodeficiency virus antibody screening assay. J Virol Methods. 75:27–38. DOI: 10.1016/S0166-0934(98)00094-9. PMID: 9820572.

4. Krasowski MD, Wier D, Smith S, Riedel A, Lauseker-Hao Y, Kelner M, et al. 2021; Real-world clinical performance evaluation of a fourth-generation HIV antigen/antibody differentiation test. J Appl Lab Med. 6:1417–32. DOI: 10.1093/jalm/jfab069. PMID: 34333654.

5. Stone M, Bainbridge J, Sanchez AM, Keating SM, Pappas A, Rountree W, et al. 2018; Comparison of detection limits of fourth- and fifth-generation combination HIV Aantigen-antibody, p24 antigen, and viral load assays on diverse HIV isolates. J Clin Microbiol. 56:e02045–17. DOI: 10.1128/JCM.02045-17. PMID: 29793968. PMCID: PMC6062817.

6. Peruski AH, Wesolowski LG, Delaney KP, Chavez PR, Owen SM, Granade TC, et al. 2020; Trends in HIV-2 diagnoses and use of the HIV-1/HIV-2 differentiation test - United States, 2010-2017. MMWR Morb Mortal Wkly Rep. 69:63–6. DOI: 10.15585/mmwr.mm6903a2. PMID: 31971928. PMCID: PMC7367036.

7. Nam JG, Kim GJ, Baek JY, Suh SD, Kee MK, Lee JS, et al. 2006; Molecular investigation of human immunodeficiency virus type 2 subtype a cases in South Korea. J Clin Microbiol. 44:1543–6. DOI: 10.1128/JCM.44.4.1543-1546.2006. PMID: 16597889. PMCID: PMC1448639.

8. Berzow D, Descamps D, Obermeier M, Charpentier C, Kaiser R, Guertler L, et al. 2021; Human immunodeficiency virus-2 (HIV-2): a summary of the present standard of care and treatment options for individuals living with HIV-2 in Western Europe. Clin Infect Dis. 72:503–9. DOI: 10.1093/cid/ciaa275. PMID: 32227124.

9. Clinical and Laboratory Standards Institute. 2014. Evaluation of precision of quantitative measurement procedures; Approved guideline-Third edition. CLSI document EP05-A3. Clinical and Laboratory Standards Institute;Wayne, PA:

10. Clinical and Laboratory Standards Institute. 2006. Preliminary evaluation of quantitative clinical laboratory measurement procedures; Approved guideline-Third edition. CLSI document EP10-A3. Clinical and Laboratory Standards Institute;Wayne, PA:

11. Mitchell EO, Stewart G, Bajzik O, Ferret M, Bentsen C, Shriver MK. 2013; Performance comparison of the 4th generation Bio-Rad Laboratories GS HIV Combo Ag/Ab EIA on the EVOLIS™ automated system versus Abbott ARCHITECT HIV Ag/Ab Combo, Ortho Anti-HIV 1+2 EIA on Vitros ECi and Siemens HIV-1/O/2 enhanced on Advia Centaur. J Clin Virol. 58(1S):e79–84. DOI: 10.1016/j.jcv.2013.08.009. PMID: 24342482.

12. Kang HJ, Yoo KH, Kim HS, Cho HC. 2006; Evaluation of Abbott fourth generation HIV antigen and antibody assays. Korean J Lab Med. 26:39–44. DOI: 10.3343/kjlm.2006.26.1.39. PMID: 18156698.

13. Jung BK, Kim HN, Choi JS, Shin K, Lee CK, Cho Y. 2014; Performance of the Elecsys HIV combi PT assay compared to the ARCHITECT HIV Ag/Ab Combo assay. Lab Med Online. 4:157–63. DOI: 10.3343/lmo.2014.4.3.157.

14. Mühlbacher A, Schennach H, van Helden J, Hebell T, Pantaleo G, Bürgisser P, et al. 2013; Performance evaluation of a new fourth-generation HIV combination antigen-antibody assay. Med Microbiol Immunol. 202:77–86. DOI: 10.1007/s00430-012-0250-5. PMID: 22706797. PMCID: PMC3562432.

15. Song EY, Hur M, Roh EY, Park MH, Moon HW, Yun YM. 2012; Performances of four fourth-generation human immunodeficiency virus-1 screening assays. J Med Virol. 84:1884–8. DOI: 10.1002/jmv.23423. PMID: 23080491.

16. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, et al. 2003; Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS. 17:1871–9. DOI: 10.1097/00002030-200309050-00005. PMID: 12960819.

17. Adhikari EH, Macias D, Gaffney D, White S, Rogers VL, McIntire DD, et al. 2018; Diagnostic accuracy of fourth-generation ARCHITECT HIV Ag/Ab Combo assay and utility of signal-to-cutoff ratio to predict false-positive HIV tests in pregnancy. Am J Obstet Gynecol. 219:408.e1–9. DOI: 10.1016/j.ajog.2018.06.008. PMID: 29913173.

18. Zucker J, Carnevale C, Gordon P, Sobieszczyk ME, Rai AJ. 2022; Am I positive? Improving human immunodeficiency virus testing in the era of preexposure prophylaxis and immediate antiretroviral therapy using machine learning. Open Forum Infect Dis. 9:ofac259. DOI: 10.1093/ofid/ofac259. PMID: 35854989. PMCID: PMC9290571.

19. Lu X, Zhang M, Liu W, Sheng N, Du Q, Zhang M, et al. 2021; A method to alleviate false-positive results of the Elecsys HIV combi PT assay. Sci Rep. 11:1033. DOI: 10.1038/s41598-020-80047-0. PMID: 33441741. PMCID: PMC7807026.

20. Vallefuoco L, Aden Abdi F, Sorrentino R, Spalletti-Cernia D, Mazzarella C, Barbato S, et al. 2014; Evaluation of the siemens HIV antigen-antibody immunoassay. Intervirology. 57:106–11. DOI: 10.1159/000358879. PMID: 24557036.

21. Cui C, Liu P, Feng Z, Xin R, Yan C, Li Z. 2015; Evaluation of the clinical effectiveness of HIV antigen/antibody screening using a chemiluminescence microparticle immunoassay. J Virol Methods. 214:33–6. DOI: 10.1016/j.jviromet.2014.07.026. PMID: 25173424.

22. Korea Disease Control and Prevention Agency. Annual Report on the Notified HIV/AIDS in Korea 2021. https://npt.kdca.go.kr/npt/biz/npp/portal/nppPblctDtaView.do?pblctDtaSeAt=1&pblctDtaSn=2645. Last accessed on August 2023.

23. World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. https://apps.who.int/iris/rest/bitstreams/1357089/retrieve. Updated on Jul 2021.

24. Greig JR, Batchelor D, Wallis M. 2013; Positive predictive value is poor in low risk populations seen in universal screening for HIV infection. BMJ. 346:f3575. DOI: 10.1136/bmj.f3575. PMID: 23737279.

25. Kim S, Lee JH, Choi JY, Kim JM, Kim HS. 2010; False-positive rate of a "fourth-generation" HIV antigen/antibody combination assay in an area of low HIV prevalence. Clin Vaccine Immunol. 17:1642–4. DOI: 10.1128/CVI.00258-10. PMID: 20685938. PMCID: PMC2952989.

26. Gudipati S, Shallal A, Peterson E, Cook B, Markowitz N. Increase in false positive fourth generation HIV tests in patients with COVID-19 disease. Clin Infect Dis. 2023; ciad264.

27. Alfie LG, Longueira YS, Pippo M, Cruces L, Quiroga MF, Turk G, et al. 2023; Increased risk of false-positive HIV ELISA results after COVID-19. AIDS. 37:947–50. DOI: 10.1097/QAD.0000000000003507. PMID: 36779499. PMCID: PMC10089928.

28. Eaton JW, Johnson CC, Gregson S. 2017; The cost of not retesting: human immunodeficiency virus misdiagnosis in the antiretroviral therapy "Test-and-Offer" era. Clin Infect Dis. 65:522–5. DOI: 10.1093/cid/cix341. PMID: 28444206. PMCID: PMC5850410.

29. Dougan S, Patel B, Tosswill JH, Sinka K. 2005; Diagnoses of HIV-1 and HIV-2 in England, Wales, and Northern Ireland associated with west Africa. Sex Transm Infect. 81:338–41. DOI: 10.1136/sti.2004.013011. PMID: 16061543. PMCID: PMC1745000.

30. Matheron S, Pueyo S, Damond F, Simon F, Leprêtre A, Campa P, et al. 2003; Factors associated with clinical progression in HIV-2 infected-patients: the French ANRS cohort. AIDS. 17:2593–601. DOI: 10.1097/00002030-200312050-00006. PMID: 14685053.

31. Korea Disease Control and Prevention Agency. 2023 HIV/AIDS Management Guidelines. https://www.kdca.go.kr/filepath/boardDownload.es?bid=0019&list_no=722271&seq=1. Updated on Apr 2023.